{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:00:22Z","timestamp":1790370022569,"version":"4.1.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40265-026-02369-z","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:11:18Z","timestamp":1789200678000},"page":"1645-1660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current and Emerging Biomarkers and Surrogate Endpoints in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-0406","authenticated-orcid":false,"given":"Mariam","family":"Alamgir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aalam","family":"Sohal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"issue":"6","key":"2369_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"issue":"1","key":"2369_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2023.100485.PMCID:PMC10824973","volume":"65","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Sookoian S. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. J Lipid Res. 2024;65(1):100485. https:\/\/doi.org\/10.1016\/j.jlr.2023.100485.PMCID:PMC10824973.","journal-title":"J Lipid Res"},{"issue":"2","key":"2369_CR3","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.jhep.2023.08.008","volume":"80","author":"V Ratziu","year":"2024","unstructured":"Ratziu V, Boursier J. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol. 2024;80(2):e51\u20132. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.008.","journal-title":"J Hepatol"},{"issue":"1","key":"2369_CR4","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/j.jhep.2023.07.021","volume":"80","author":"SJ Song","year":"2024","unstructured":"Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80(1):e45\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.021.","journal-title":"J Hepatol"},{"issue":"1","key":"2369_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54707","volume":"8","author":"P Le","year":"2025","unstructured":"Le P, Tatar M, Dasarathy S, Alkhouri N, Herman WH, Taksler GB, et al. Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025;8(1):e2454707. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.54707. (PMID: 39821400; PMCID: PMC11742522).","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2369_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jceh.2019.09.005","volume":"10","author":"A De","year":"2020","unstructured":"De A, Duseja A. Natural history of simple steatosis or nonalcoholic fatty liver. J Clin Exp Hepatol. 2020;10(3):255\u201362. https:\/\/doi.org\/10.1016\/j.jceh.2019.09.005. (PMID: 32405182; PMCID: PMC7212297).","journal-title":"J Clin Exp Hepatol"},{"key":"2369_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fgstr.2025.1699508","volume":"4","author":"HD Purnomo","year":"2025","unstructured":"Purnomo HD, Adiwinata R, Permatadewi CO, Hutami HT, Indiarso D. The global landscape of lean metabolic dysfunction-associated steatotic liver disease: insight from Asia and the West. Front Gastroenterol. 2025;4:1699508. https:\/\/doi.org\/10.3389\/fgstr.2025.1699508.","journal-title":"Front Gastroenterol"},{"issue":"9 Suppl","key":"2369_CR8","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.37765\/ajmc.2024.89635","volume":"30","author":"N Alkhouri","year":"2024","unstructured":"Alkhouri N, Noureddin M. Management strategies for metabolic dysfunction-associated steatotic liver disease (MASLD). Am J Manag Care. 2024Nov;30(9 Suppl):S159\u201374. https:\/\/doi.org\/10.37765\/ajmc.2024.89635. (PMID: 39513734).","journal-title":"Am J Manag Care"},{"issue":"17","key":"2369_CR9","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559\u201369. https:\/\/doi.org\/10.1056\/NEJMoa2029349. (PMID: 34670043; PMCID: PMC8881985).","journal-title":"N Engl J Med"},{"issue":"17","key":"2369_CR10","doi-asserted-by":"publisher","first-page":"175628482412763","DOI":"10.1177\/17562848241276334","volume":"14","author":"D Hudson","year":"2024","unstructured":"Hudson D, Afzaal T, Bualbanat H, AlRamdan R, Howarth N, Parthasarathy P, et al. Modernizing metabolic dysfunction-associated steatotic liver disease diagnostics: the progressive shift from liver biopsy to noninvasive techniques. Ther Adv Gastroenterol. 2024;14(17):17562848241276334. https:\/\/doi.org\/10.1177\/17562848241276334. (PMID: 39553445; PMCID: PMC11565685).","journal-title":"Ther Adv Gastroenterol"},{"issue":"3","key":"2369_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"A Berzigotti","year":"2021","unstructured":"European Association for the Study of the Liver, Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, et al. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J Hepatol. 2021;75(3):659\u201389. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025. (PMID: 34166721).","journal-title":"J Hepatol"},{"issue":"10464","key":"2369_CR12","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","volume":"404","author":"M Israelsen","year":"2024","unstructured":"Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet. 2024;404(10464):1761\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(24)01811-7.","journal-title":"Lancet"},{"key":"2369_CR13","unstructured":"Sanyal A, Shankar S, Yates K, Bolognese J, Daly E, Dehn C, et al. The Nimble Stage 1 Study validates diagnostic circulating biomarkers for nonalcoholic steatohepatitis. Preprint. Res Square. 2023. https:\/\/www.researchsquare.com\/article\/rs-2492725\/v1. Cited 26 Feb 2025."},{"issue":"9","key":"2369_CR14","doi-asserted-by":"publisher","first-page":"925","DOI":"10.7150\/ijms.8951","volume":"11","author":"Z Liu","year":"2014","unstructured":"Liu Z, Que S, Xu J, Peng T. Alanine aminotransferase \u2014 old biomarker and new concept: a review. Int J Med Sci. 2014;11(9):925\u201335. https:\/\/doi.org\/10.7150\/ijms.8951.","journal-title":"Int J Med Sci"},{"issue":"42","key":"2369_CR15","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.3748\/wjg.v30.i42.4576","volume":"30","author":"TN Moyana","year":"2024","unstructured":"Moyana TN. Metabolic dysfunction-associated steatotic liver disease: the question of long-term high-normal alanine aminotransferase as a screening test. World J Gastroenterol. 2024;30(42):4576\u201382. https:\/\/doi.org\/10.3748\/wjg.v30.i42.4576. (PMID: 39563746; PMCID: PMC11572615).","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2369_CR16","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/hep.22429","volume":"48","author":"AL Fracanzani","year":"2008","unstructured":"Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792\u20138. https:\/\/doi.org\/10.1002\/hep.22429. (PMID: 18752331).","journal-title":"Hepatology"},{"key":"2369_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2025.09.003","author":"A De","year":"2025","unstructured":"De A, Chalasani N, Duseja A. Biomarkers in metabolic dysfunction-associated steatotic liver disease. Gastroenterol Clin N Am. 2025. https:\/\/doi.org\/10.1016\/j.gtc.2025.09.003. (Epub ahead of print).","journal-title":"Gastroenterol Clin N Am"},{"issue":"5","key":"2369_CR18","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"issue":"2","key":"2369_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/hep.29797","volume":"68","author":"C Caussy","year":"2018","unstructured":"Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018;68(2):763\u201372.","journal-title":"Hepatology"},{"issue":"4","key":"2369_CR20","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/hep.29285","volume":"66","author":"KA So-Armah","year":"2017","unstructured":"So-Armah KA, Lim JK, Lo Re V, Tate JP, Chang CH, Butt AA, et al. FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. Hepatology. 2017;66(4):1286\u201395. https:\/\/doi.org\/10.1002\/hep.29285. (PMID: 28543215; PMCID: PMC5609079).","journal-title":"Hepatology"},{"issue":"11","key":"2369_CR21","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/liv.14198","volume":"39","author":"C Crossan","year":"2019","unstructured":"Crossan C, Majumdar A, Srivastava A, Thorburn D, Rosenberg W, Pinzani M, et al. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: diagnostic accuracy and cost analysis. Liver Int. 2019;39(11):2052\u201360. https:\/\/doi.org\/10.1111\/liv.14198.","journal-title":"Liver Int"},{"issue":"3","key":"2369_CR22","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep.24105","volume":"53","author":"ZH Lin","year":"2011","unstructured":"Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726\u201336. https:\/\/doi.org\/10.1002\/hep.24105. (PMID: 21319189).","journal-title":"Hepatology"},{"issue":"11","key":"2369_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.7326\/0003-4819-158-11-201306040-00005","volume":"158","author":"R Chou","year":"2013","unstructured":"Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013;158(11):807\u201320. https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00005.","journal-title":"Ann Intern Med"},{"issue":"11","key":"2369_CR24","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3748\/wjg.v25.i11.1307","volume":"25","author":"JH Zhou","year":"2019","unstructured":"Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice. World J Gastroenterol. 2019;25(11):1307\u201326. https:\/\/doi.org\/10.3748\/wjg.v25.i11.1307. (PMID: 30918425; PMCID: PMC6429343).","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2369_CR25","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846\u201354. https:\/\/doi.org\/10.1002\/hep.21496. (PMID: 17393509).","journal-title":"Hepatology"},{"key":"2369_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.70281","author":"F Lin","year":"2025","unstructured":"Lin F, Obeid A, Sharma M, Kaur P, Chaput K, Liaquat H. Diagnostic performance of fibrosis 4 index, NAFLD fibrosis score, AST to platelet ratio index, and BARD score among young and older adults for advanced MASLD fibrosis: a retrospective cohort study. JGH Open. 2025. https:\/\/doi.org\/10.1002\/jgh3.70281. (Epub ahead of print).","journal-title":"JGH Open."},{"issue":"16\u201317","key":"2369_CR27","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.clinbiochem.2008.06.020","volume":"41","author":"V Leroy","year":"2008","unstructured":"Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourli\u00e8re M, et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem. 2008;41(16\u201317):1368\u201376. https:\/\/doi.org\/10.1016\/j.clinbiochem.2008.06.020. (PMID: 18655779).","journal-title":"Clin Biochem"},{"key":"2369_CR28","doi-asserted-by":"publisher","unstructured":"Arvaniti P, Giannoulis G, Lygoura V, Gatselis NK, Gabeta S, Rigopoulou E, Koukoulis GK, Zachou K, Dalekos GN. FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease. Ann Gastroenterol. 2023;36(6):661\u20139. https:\/\/doi.org\/10.20524\/aog.2023.0841(PMID: 38023979; PMCID: PMC10662069).","DOI":"10.20524\/aog.2023.0841"},{"issue":"13","key":"2369_CR29","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.3390\/jcm10132910","volume":"10","author":"AM Van Dijk","year":"2021","unstructured":"Van Dijk AM, Vali Y, Mak AL, Lee J, Tushuizen ME, Zafarmand MH, et al. Systematic review with meta-analyses: diagnostic accuracy of FibroMeter tests in patients with NAFLD. J Clin Med. 2021;10(13):2910. https:\/\/doi.org\/10.3390\/jcm10132910.","journal-title":"J Clin Med"},{"issue":"13","key":"2369_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14131317","volume":"14","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, Takaura K, Higuchi M, Yasui Y, Itakura J, Tsuchiya K, et al. Enhanced liver fibrosis score for diagnosing liver fibrosis in chronic hepatitis. Diagnostics (Basel). 2024;14(13):1317. https:\/\/doi.org\/10.3390\/diagnostics14131317.","journal-title":"Diagnostics (Basel)"},{"issue":"6","key":"2369_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101062","volume":"6","author":"M Pearson","year":"2024","unstructured":"Pearson M, Nobes J, Macpherson I, Gold L, Miller M, Dow E, et al. Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality. JHEP Rep. 2024;6(6):101062. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101062. (PMID: 38826498; PMCID: PMC11141136).","journal-title":"JHEP Rep."},{"issue":"2","key":"2369_CR32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","volume":"73","author":"Y Vali","year":"2020","unstructured":"Vali Y, Lee J, Boursier J, Spijker R, L\u00f6ffler J, Verheij J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2020;73(2):252\u201362. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.036. (PMID: 32275982).","journal-title":"J Hepatol"},{"issue":"7","key":"2369_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100765","volume":"5","author":"K Saarinen","year":"2023","unstructured":"Saarinen K, F\u00e4rkkil\u00e4 M, Jula A, Erlund I, Vihervaara T, Lundqvist A, et al. Enhanced liver fibrosis\u00ae test predicts liver-related outcomes in the general population. JHEP Rep. 2023;5(7):100765. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100765.","journal-title":"JHEP Rep"},{"key":"2369_CR34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12020-022-03157-x","volume":"78","author":"A Salmi","year":"2022","unstructured":"Salmi A, di Filippo L, Ferrari C, et al. Ultrasound and FibroScan\u00ae controlled attenuation parameter in patients with MAFLD: head-to-head comparison in assessing liver steatosis. Endocrine. 2022;78:262\u20139. https:\/\/doi.org\/10.1007\/s12020-022-03157-x.","journal-title":"Endocrine"},{"issue":"8","key":"2369_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2025.103337","volume":"56","author":"C Gofton","year":"2025","unstructured":"Gofton C, George J. Non-invasive testing in metabolic dysfunction-associated fatty liver disease. Arch Med Res. 2025;56(8):103337. https:\/\/doi.org\/10.1016\/j.arcmed.2025.103337.","journal-title":"Arch Med Res"},{"issue":"9","key":"2369_CR36","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/liv.12840","volume":"35","author":"F Bril","year":"2015","unstructured":"Bril F, Ortiz-Lopez C, Lomonaco R, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int. 2015;35(9):2139\u201346. https:\/\/doi.org\/10.1111\/liv.12840.","journal-title":"Liver Int"},{"issue":"2","key":"2369_CR37","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.241171","volume":"313","author":"M Haghshomar","year":"2024","unstructured":"Haghshomar M, Antonacci D, Smith AD, et al. Diagnostic accuracy of CT for the detection of hepatic steatosis: a systematic review and meta-analysis. Radiology. 2024;313(2):e241171. https:\/\/doi.org\/10.1148\/radiol.241171.","journal-title":"Radiology"},{"issue":"1","key":"2369_CR38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.5334\/jbsr.4132","volume":"109","author":"PJ Pickhardt","year":"2025","unstructured":"Pickhardt PJ. Understanding MASLD: steatosis, MASH, fibrosis, and metabolic syndrome. J Belg Soc Radiol. 2025;109(1):60. https:\/\/doi.org\/10.5334\/jbsr.4132.","journal-title":"J Belg Soc Radiol."},{"issue":"5","key":"2369_CR39","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jhep.2014.01.005","volume":"60","author":"V De L\u00e9dinghen","year":"2014","unstructured":"De L\u00e9dinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart JB, Cassinotto C, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014;60(5):1026\u201331. https:\/\/doi.org\/10.1016\/j.jhep.2014.01.005.","journal-title":"J Hepatol"},{"key":"2369_CR40","doi-asserted-by":"publisher","unstructured":"Petroff D, Newsome PN, Shalimar, et al. Assessment of hepatic steatosis by controlled attenuation parameter using M and XL probes: an individual patient meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(3):185\u201395. https:\/\/doi.org\/10.1016\/S2468-1253(20)30357-5.","DOI":"10.1016\/S2468-1253(20)30357-5"},{"issue":"5","key":"2369_CR41","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","volume":"48","author":"L Castera","year":"2008","unstructured":"Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835\u201347. https:\/\/doi.org\/10.1016\/j.jhep.2008.02.008. (PMID: 18334275).","journal-title":"J Hepatol"},{"issue":"6","key":"2369_CR42","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717\u201330. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.042. (PMID: 30689971).","journal-title":"Gastroenterology"},{"key":"2369_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101547","volume":"51","author":"Y Cao","year":"2022","unstructured":"Cao Y, Xiang L, Qi F, Zhang Y, Chen Y, Zhou X. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in nonalcoholic fatty liver disease: a systematic review and meta-analysis. eClinicalMedicine. 2022;51:101547. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101547.","journal-title":"eClinicalMedicine"},{"issue":"1","key":"2369_CR44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","volume":"17","author":"MS Siddiqui","year":"2019","unstructured":"Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(1):156-163.e2. https:\/\/doi.org\/10.1016\/j.cgh.2018.04.043. (PMID: 29705261; PMCID: PMC6203668).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2369_CR45","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R De Franchis","year":"2022","unstructured":"De Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII \u2013 renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.022.","journal-title":"J Hepatol"},{"issue":"2","key":"2369_CR46","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","volume":"81","author":"RK Sterling","year":"2025","unstructured":"Sterling RK, Duarte-Rojo A, Patel K, Asrani SK, Alsawas M, Dranoff JA, et al. AASLD practice guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology. 2025;81(2):672\u2013724. https:\/\/doi.org\/10.1097\/HEP.0000000000000843.","journal-title":"Hepatology"},{"issue":"1","key":"2369_CR47","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","volume":"81","author":"VL Chen","year":"2025","unstructured":"Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Wong VW, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance. Hepatology. 2025Jan;81(1):312\u201320. https:\/\/doi.org\/10.1097\/HEP.0000000000001112.","journal-title":"Hepatology"},{"key":"2369_CR48","unstructured":"American Association for the Study of Liver Diseases. AASLD applauds FDA approval of first GLP-1 therapy for MASH, expanding use of popular weight loss drug to liver disease [Internet]. AASLD. https:\/\/www.aasld.org\/aasld-applauds-fda-approval-first-glp-1-therapy-mash-expanding-use-popular-weight-loss-drug-liver. Cited 12 June 2026."},{"issue":"1","key":"2369_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.14366\/usg.19013","volume":"39","author":"J Yoo","year":"2020","unstructured":"Yoo J, Lee JM, Joo I, Yoon JH. Assessment of liver fibrosis using 2-dimensional shear wave elastography: a prospective study of intra- and inter-observer repeatability and comparison with point shear wave elastography. Ultrasonography. 2020;39(1):52\u20139. https:\/\/doi.org\/10.14366\/usg.19013. (PMID: 31623416; PMCID: PMC6920625).","journal-title":"Ultrasonography"},{"issue":"1","key":"2369_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010138","volume":"13","author":"A Liguori","year":"2025","unstructured":"Liguori A, Esposto G, Ainora ME, Mignini I, Borriello R, Galasso L, et al. Liver elastography for liver fibrosis stratification: a comparison of three techniques in a biopsy-controlled MASLD cohort. Biomedicines. 2025;13(1):138. https:\/\/doi.org\/10.3390\/biomedicines13010138.","journal-title":"Biomedicines"},{"issue":"13","key":"2369_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15131598","volume":"15","author":"MP Wilson","year":"2025","unstructured":"Wilson MP, Singh R, Mehta S, Murad MH, Fung C, Low G. Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE thresholds and diagnostic accuracies for detecting hepatic fibrosis in patients with MASLD: a systematic review and meta-analysis. Diagnostics (Basel). 2025;15(13):1598. https:\/\/doi.org\/10.3390\/diagnostics15131598.","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"2369_CR52","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/HEP.0000000000001190","volume":"82","author":"MG Indre","year":"2025","unstructured":"Indre MG, Leucuta DC, Lupsor-Platon M, Turco L, Ferri S, Hashim A, et al. Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: a multilevel random effects model meta-analysis. Hepatology. 2025;82(2):454\u201369. https:\/\/doi.org\/10.1097\/HEP.0000000000001190.","journal-title":"Hepatology"},{"issue":"1","key":"2369_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5152\/dir.2021.21845","volume":"28","author":"IS Idilman","year":"2022","unstructured":"Idilman IS. Proton density fat fraction: magnetic resonance imaging applications beyond the liver. Diagn Interv Radiol. 2022;28(1):83\u201391. https:\/\/doi.org\/10.5152\/dir.2021.21845.","journal-title":"Diagn Interv Radiol"},{"issue":"3","key":"2369_CR54","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/hep.25731","volume":"56","author":"TA Le","year":"2012","unstructured":"Le TA, Chen J, Changchien C, Peterson MR, Kono Y, Patton H, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology. 2012;56(3):922\u201332. https:\/\/doi.org\/10.1002\/hep.25731.","journal-title":"Hepatology"},{"issue":"6","key":"2369_CR55","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000. (PMID: 38324483).","journal-title":"N Engl J Med"},{"issue":"5","key":"2369_CR56","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/gutjnl-2021-324264","volume":"71","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Munaganuru N, Jung J, Yonan AQ, Loomba RR, Bettencourt R, et al. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut. 2022;71(5):983\u201390. https:\/\/doi.org\/10.1136\/gutjnl-2021-324264.","journal-title":"Gut"},{"issue":"4","key":"2369_CR57","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1007\/s00330-024-11001-1","volume":"35","author":"N Azizi","year":"2025","unstructured":"Azizi N, Naghibi H, Shakiba M, Morsali M, Zarei D, Abbastabar H, et al. Evaluation of MRI proton density fat fraction in hepatic steatosis: a systematic review and meta-analysis. Eur Radiol. 2025;35(4):1794\u2013807. https:\/\/doi.org\/10.1007\/s00330-024-11001-1.","journal-title":"Eur Radiol"},{"issue":"5","key":"2369_CR58","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","volume":"65","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65(5):1006\u201316. https:\/\/doi.org\/10.1016\/j.jhep.2016.06.005.","journal-title":"J Hepatol"},{"issue":"5","key":"2369_CR59","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00330-015-3949-z","volume":"26","author":"S Singh","year":"2016","unstructured":"Singh S, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol. 2016;26(5):1431\u201340. https:\/\/doi.org\/10.1007\/s00330-015-3949-z.","journal-title":"Eur Radiol"},{"key":"2369_CR60","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221093869","volume":"15","author":"V Ajmera","year":"2022","unstructured":"Ajmera V, Nguyen K, Tamaki N, Sharpton S, Bettencourt R, Loomba R. Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2022;15:17562848221093869. https:\/\/doi.org\/10.1177\/17562848221093869.","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"2369_CR61","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1053\/j.gastro.2022.06.073","volume":"163","author":"V Ajmera","year":"2022","unstructured":"Ajmera V, Kim BK, Yang K, Majzoub AM, Nayfeh T, Tamaki N, et al. Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants. Gastroenterology. 2022;163(4):1079-89.e5. https:\/\/doi.org\/10.1053\/j.gastro.2022.06.073. (PMID: 35788083).","journal-title":"Gastroenterology"},{"key":"2369_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16589","author":"S Qi","year":"2024","unstructured":"Qi S, Wang X, Guo H, Hu J, Wang Q, Zhang N, et al. Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis. J Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1111\/jgh.16589.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"2369_CR63","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12876-024-03270-3","volume":"24","author":"Z Liu","year":"2024","unstructured":"Liu Z, Ren Q, Mu H, Zeng Y, An Z, He H. Preliminary study on the diagnostic value of LEAP-2 and CK18 in biopsy-proven MAFLD. BMC Gastroenterol. 2024;24(1):182. https:\/\/doi.org\/10.1186\/s12876-024-03270-3.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"2369_CR64","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/hep.31622","volume":"73","author":"R Loomba","year":"2021","unstructured":"Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology. 2021;73(2):625\u201343. https:\/\/doi.org\/10.1002\/hep.31622.","journal-title":"Hepatology"},{"issue":"8","key":"2369_CR65","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.gastha.2024.08.005","volume":"3","author":"M Kawanaka","year":"2024","unstructured":"Kawanaka M, Kamada Y, Takahashi H, Iwaki M, Nishino K, Zhao W, et al. Serum cytokeratin 18 fragment is an indicator for treating metabolic dysfunction-associated steatotic liver disease. Gastro Hep Adv. 2024;3(8):1120\u20138. https:\/\/doi.org\/10.1016\/j.gastha.2024.08.005.","journal-title":"Gastro Hep Adv."},{"issue":"1","key":"2369_CR66","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/hep.30610","volume":"70","author":"C Caussy","year":"2019","unstructured":"Caussy C, Bhargava M, Villesen IF, Gudmann NS, Leeming DJ, Karsdal MA, et al. Collagen formation assessed by N-terminal propeptide of type 3 procollagen is a heritable trait and is associated with liver fibrosis assessed by magnetic resonance elastography. Hepatology. 2019;70(1):127\u201341. https:\/\/doi.org\/10.1002\/hep.30610. (PMID: 30859582; PMCID: PMC6984974).","journal-title":"Hepatology"},{"issue":"3","key":"2369_CR67","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jhepr.2019.06.004","volume":"1","author":"M Boyle","year":"2019","unstructured":"Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianesi E, Petta S, et al. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep. 2019;1(3):188\u201398. https:\/\/doi.org\/10.1016\/j.jhepr.2019.06.004. (PMID: 32039369; PMCID: PMC7001575).","journal-title":"JHEP Rep."},{"issue":"1","key":"2369_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30457-y","volume":"8","author":"Y Luo","year":"2018","unstructured":"Luo Y, Oseini A, Gagnon R, Charles ED, Sidik K, Vincent R, et al. An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis. Sci Rep. 2018;8(1):12414. https:\/\/doi.org\/10.1038\/s41598-018-30457-y.","journal-title":"Sci Rep"},{"issue":"2","key":"2369_CR69","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2174\/1566523214666141224095610","volume":"15","author":"S Thakral","year":"2015","unstructured":"Thakral S, Ghoshal K. miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir. Curr Gene Ther. 2015;15(2):142\u201350. https:\/\/doi.org\/10.2174\/1566523214666141224095610. (PMID: 25537773; PMCID: PMC4439190).","journal-title":"Curr Gene Ther"},{"key":"2369_CR70","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s13105-025-01110-w","volume":"81","author":"AL Tobaruela-Resola","year":"2025","unstructured":"Tobaruela-Resola AL, Milagro FI, Mogna-Pelaez P, et al. The use of circulating miRNAs for the diagnosis, prognosis, and personalized treatment of MASLD. J Physiol Biochem. 2025;81:589\u2013609. https:\/\/doi.org\/10.1007\/s13105-025-01110-w.","journal-title":"J Physiol Biochem"},{"issue":"6","key":"2369_CR71","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/hep.22569","volume":"48","author":"O Cheung","year":"2008","unstructured":"Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology. 2008;48(6):1810\u201320. https:\/\/doi.org\/10.1002\/hep.22569.","journal-title":"Hepatology"},{"issue":"4","key":"2369_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101011","volume":"6","author":"QM Anstee","year":"2024","unstructured":"Anstee QM, Magnanensi J, Hajji Y, Caron A, Majd Z, Rosenquist C, et al. Impact of age on NIS2+\u2122 and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH. JHEP Rep. 2024;6(4):101011. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101011.","journal-title":"JHEP Rep"},{"issue":"11","key":"2369_CR73","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","volume":"5","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(11):970\u201385. https:\/\/doi.org\/10.1016\/S2468-1253(20)30252-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"2369_CR74","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","volume":"79","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, et al. NIS2+\u2122, an optimisation of the blood-based biomarker NIS4\u00ae technology for the detection of at-risk NASH: a prospective derivation and validation study. J Hepatol. 2023;79(3):758\u201367. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.031.","journal-title":"J Hepatol"},{"key":"2369_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1400961","volume":"15","author":"B Ramos-Molina","year":"2024","unstructured":"Ramos-Molina B, Rossell J, P\u00e9rez-Montes De Oca A, Pardina E, Genua I, Rojo-L\u00f3pez MI, et al. Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis. Front Endocrinol (Lausanne). 2024;15:1400961. https:\/\/doi.org\/10.3389\/fendo.2024.1400961.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2369_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14010012","volume":"14","author":"MM Syed-Abdul","year":"2023","unstructured":"Syed-Abdul MM. Lipid metabolism in metabolic-associated steatotic liver disease (MASLD). Metabolites. 2023;14(1):12. https:\/\/doi.org\/10.3390\/metabo14010012.","journal-title":"Metabolites"},{"issue":"5","key":"2369_CR77","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000531946","volume":"16","author":"G Lassailly","year":"2023","unstructured":"Lassailly G, Caussy C, Hollebecque A, et al. Metabolic dysfunction-associated steatotic liver disease in severe obesity and concordance between invasive (biopsy) and noninvasive (OWLiver\u00ae) diagnoses. Obes Facts. 2023;16(5):456\u201368. https:\/\/doi.org\/10.1159\/000531946.","journal-title":"Obes Facts"},{"issue":"7","key":"2369_CR78","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/hep4.1188","volume":"2","author":"R Mayo","year":"2018","unstructured":"Mayo R, Crespo J, Mart\u00ednez-Arranz I, Banales JM, Arias M, Minchol\u00e9 I, et al. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts. Hepatol Commun. 2018;2(7):807\u201320. https:\/\/doi.org\/10.1002\/hep4.1188.","journal-title":"Hepatol Commun"},{"issue":"1","key":"2369_CR79","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","volume":"79","author":"M Noureddin","year":"2024","unstructured":"Noureddin M, Truong E, Mayo R, Mart\u00ednez-Arranz I, Minchol\u00e9 I, Banales JM, et al. Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF). Hepatology. 2024;79(1):135\u201348. https:\/\/doi.org\/10.1097\/HEP.0000000000000542.","journal-title":"Hepatology"},{"issue":"4","key":"2369_CR80","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40139-015-0094-y","volume":"3","author":"PH Park","year":"2015","unstructured":"Park PH, Sanz-Garcia C, Nagy LE. Adiponectin as an anti-fibrotic and anti-inflammatory adipokine in the liver. Curr Pathobiol Rep. 2015;3(4):243\u201352. https:\/\/doi.org\/10.1007\/s40139-015-0094-y. (PMID: 26858914; PMCID: PMC4743902).","journal-title":"Curr Pathobiol Rep."},{"issue":"30","key":"2369_CR81","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.1016\/j.febslet.2005.11.019","volume":"579","author":"N Yamaguchi","year":"2005","unstructured":"Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M, Nonaka K, Saito T, et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett. 2005;579(30):6821\u20136. https:\/\/doi.org\/10.1016\/j.febslet.2005.11.019.","journal-title":"FEBS Lett"},{"issue":"6","key":"2369_CR82","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","volume":"43","author":"ML Hartman","year":"2020","unstructured":"Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43(6):1352\u20135. https:\/\/doi.org\/10.2337\/dc19-1892. (PMID: 32291277; PMCID: PMC7245348).","journal-title":"Diabetes Care"},{"issue":"5","key":"2369_CR83","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/CRD.0000000000000625","volume":"33","author":"NN Bailey","year":"2025","unstructured":"Bailey NN, Peterson SJ, Parikh MA, Jackson KA, Frishman WH. Pegozafermin is a potential master therapeutic regulator in metabolic disorders: a review. Cardiol Rev. 2025;33(5):402\u20136. https:\/\/doi.org\/10.1097\/CRD.0000000000000625. (PMID: 37889055; PMCID: PMC12321333).","journal-title":"Cardiol Rev"},{"issue":"3","key":"2369_CR84","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1464-5491.2006.01776.x","volume":"23","author":"H Shimizu","year":"2006","unstructured":"Shimizu H, Oh-I S, Tsuchiya T, Ohtani KI, Okada S, Mori M. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in type 2 diabetic patients: a randomized study. Diabet Med. 2006;23(3):253\u20137. https:\/\/doi.org\/10.1111\/j.1464-5491.2006.01776.x. (PMID: 16492207).","journal-title":"Diabet Med"},{"issue":"1","key":"2369_CR85","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23(1):346. https:\/\/doi.org\/10.1186\/s12933-024-02434-5. (PMID: 39342178; PMCID: PMC11439309).","journal-title":"Cardiovasc Diabetol"},{"key":"2369_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121268","volume":"313","author":"FF Martins","year":"2023","unstructured":"Martins FF, Santos-Reis T, Marinho TS, Aguila MB, Mandarim-de-Lacerda CA. Hypothalamic anorexigenic signaling pathways (leptin, amylin, and proopiomelanocortin) are semaglutide (GLP-1 analog) targets in obesity control in mice. Life Sci. 2023;313:121268. https:\/\/doi.org\/10.1016\/j.lfs.2022.121268.","journal-title":"Life Sci"},{"issue":"4","key":"2369_CR87","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jgg.2021.09.009","volume":"49","author":"S Lu","year":"2022","unstructured":"Lu S, Wang Y, Liu J. Tumor necrosis factor-\u03b1 signaling in nonalcoholic steatohepatitis and targeted therapies. J Genet Genomics. 2022;49(4):269\u201378. https:\/\/doi.org\/10.1016\/j.jgg.2021.09.009.","journal-title":"J Genet Genomics"},{"issue":"1","key":"2369_CR88","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1038\/s41467-023-42162-0","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Li H, Zhang H, Chen X, Chen J, Xu Z, et al. ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD: a randomized, placebo-controlled phase Ib\/IIa trial. Nat Commun. 2023;14(1):6409. https:\/\/doi.org\/10.1038\/s41467-023-42162-0. (PMID: 37828034; PMCID: PMC10570369).","journal-title":"Nat Commun"},{"issue":"4","key":"2369_CR89","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1179\/1351000213Y.0000000050","volume":"18","author":"F Ucar","year":"2013","unstructured":"Ucar F, Sezer S, Erdogan S, Akyol S, Armutcu F, Akyol O. The relationship between oxidative stress and nonalcoholic fatty liver disease: its effects on the development of nonalcoholic steatohepatitis. Redox Rep. 2013;18(4):127\u201333. https:\/\/doi.org\/10.1179\/1351000213Y.0000000050. (PMID: 23743495; PMCID: PMC6837573).","journal-title":"Redox Rep"},{"issue":"5","key":"2369_CR90","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","volume":"112","author":"S McPherson","year":"2017","unstructured":"McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740\u201351. https:\/\/doi.org\/10.1038\/ajg.2016.453. (PMID: 27725647; PMCID: PMC5418560).","journal-title":"Am J Gastroenterol"},{"issue":"9972","key":"2369_CR91","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(14)61933-4.","journal-title":"Lancet"},{"issue":"11","key":"2369_CR92","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","volume":"19","author":"JG Stine","year":"2021","unstructured":"Stine JG, Munaganuru N, Barnard A, Wang JL, Kaulback K, Argo CK, et al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(11):2274-83.e5. https:\/\/doi.org\/10.1016\/j.cgh.2020.08.061. (PMID: 32882428; PMCID: PMC7914285).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"2369_CR93","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","volume":"22","author":"M Noureddin","year":"2024","unstructured":"Noureddin M, Alkhouri N, Harrison SA, Ratziu V, Sanyal AJ, Loomba R, et al. Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis. Clin Gastroenterol Hepatol. 2024;22(12):2367\u201377. https:\/\/doi.org\/10.1016\/j.cgh.2024.07.003.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2369_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.08.041","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Nakajima A, Bugianesi E, Sebastiani G, Schattenberg JM, Adams LA, et al. Expert Delphi consensus on surrogate endpoints for treatment assessment in metabolic dysfunction-associated steatohepatitis. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.08.041. ([Epub ahead of print]. PMID: 41360159).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2369_CR95","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/hep.32594","volume":"77","author":"T Gidener","year":"2023","unstructured":"Gidener T, Dierkhising RA, Mara KC, Therneau TM, Venkatesh SK, Ehman RL, et al. Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD. Hepatology. 2023;77(1):268\u201374. https:\/\/doi.org\/10.1002\/hep.32594. (PMID: 35642504; PMCID: PMC9712594).","journal-title":"Hepatology"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02369-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02369-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02369-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:07:12Z","timestamp":1790366832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02369-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":95,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2369"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02369-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No\u00a0funding was received for the preparation of this article","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kris V. Kowdley declares research support from CymaBay Therapeutics; grants and\/or contracts from 89Bio, Genfit, Gilead, GlaxoSmithKline, Hanmi, HighTide, Intercept, Madrigal, Mirum, NGM, Pfizer, Pliant, and Viking; royalties\/licenses from UpToDate; consulting fees from 89Bio, Calliditas Therapeutics, CymaBay Therapeutics, Genfit, Gilead, Inipharm, Intercept, Madrigal, Mirum, NGM, and Pliant; payment\/honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Gilead, and Intercept; participation in a data safety monitoring board or advisory board for CTI, Medpace and Labcorp; stock or stock options for Inipharm; and receipt of equipment, materials, drugs, medical writing, gifts, or other services from Sonic Insight.  Mariam Alamgir and Aalam Sohal declare no conflicts of interest.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: M.A., A.S., K.K.; Writing-Original Draft: M.A, A.S.; Writing-Review and Editing: M.A., A.S.; Visualization: A.S.; Supervision: K.K, A.S.; Project Administration: M.A.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}